title: Does ER-betacx really have no clinical importance in tamoxifen-treated breast cancer patients?
authors.forename: Carlo
authors.initials: C
authors.lastname: Palmieri
authors.forename: Ondrej
authors.initials: O
authors.lastname: Gojis
authors.forename: Bharath
authors.initials: B
authors.lastname: Rudraraju
authors.forename: Susan
authors.initials: S
authors.lastname: Cleator
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm; D047629:Estrogen Receptor beta / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D011237:Predictive Value of Tests; D020033:Protein Isoforms; D012372:ROC Curve; D015203:Reproducibility of Results; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D047629:Estrogen Receptor beta; D020033:Protein Isoforms; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen